Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG006 and Serplulimab in First-Line Extensive Stage Small-Cell Lung Cancer
NCT07231445Phase 1Recruiting
- Sponsor
- Zelgen
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, randomised trial of alveltamig in small cell lung cancer (SCLC) (2 arms), sponsored by Zelgen. Primary endpoints: Dose-limiting toxicities at 28 days and Treatment-emergent Adverse Events at 2 years. Started Apr 2026; status: recruiting.
02
Drugs
alveltamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07231445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231445.